Gain Therapeutics (GANX) EBIT (2020 - 2025)
Historic EBIT for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to -$4.8 million.
- Gain Therapeutics' EBIT fell 732.93% to -$4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.6 million, marking a year-over-year increase of 1797.26%. This contributed to the annual value of -$20.4 million for FY2024, which is 854.95% up from last year.
- Gain Therapeutics' EBIT amounted to -$4.8 million in Q3 2025, which was down 732.93% from -$5.1 million recorded in Q2 2025.
- In the past 5 years, Gain Therapeutics' EBIT ranged from a high of -$2.5 million in Q1 2021 and a low of -$8.2 million during Q2 2024
- For the 5-year period, Gain Therapeutics' EBIT averaged around -$4.7 million, with its median value being -$4.6 million (2022).
- In the last 5 years, Gain Therapeutics' EBIT crashed by 56005.52% in 2021 and then surged by 3780.23% in 2025.
- Over the past 5 years, Gain Therapeutics' EBIT (Quarter) stood at -$3.2 million in 2021, then crashed by 42.15% to -$4.6 million in 2022, then grew by 3.38% to -$4.4 million in 2023, then rose by 24.42% to -$3.3 million in 2024, then plummeted by 43.67% to -$4.8 million in 2025.
- Its EBIT was -$4.8 million in Q3 2025, compared to -$5.1 million in Q2 2025 and -$4.4 million in Q1 2025.